|
131 Companies |
|
181 Products |
|
181 Products |
|
118 Mechanisms of Action |
|
10 Trials |
|
1304 News |
|
| 12345678910111213...2627» |
- | Trial completion, Trial completion date: A Study for Older Adults With Acute Lymphoblastic Leukaemia (clinicaltrials.gov) - Aug 16, 2023
P2, N=126, Completed, Sponsor: University College, London
Unknown status --> Completed | Trial completion date: Jun 2022 --> Feb 2023
- | Campath (alemtuzumab) / Sanofi
Enrollment change, Minimal residual disease: Treatment of Relapsed T-cell Acute Lymphoblastic Leukemia or T-lymphoblastic Lymphoma With MabCampath (clinicaltrials.gov) - Mar 20, 2023
P2, N=8, Completed, Sponsor: Goethe University
Unknown status --> Completed | Trial completion date: Jun 2022 --> Feb 2023 N=25 --> 8
- ||||||| Grafalon (rabbit anti-T-lymphocyte globulin) / Mundipharma, NeoPharm
Trial completion: Study of US-ATG-F to Prevent Chronic Graft Versus Host Disease (GVHD) (clinicaltrials.gov) - Apr 20, 2019
P3, N=260, Completed, Sponsor: Neovii Biotech
N=25 --> 8 Active, not recruiting --> Completed
- || Adcetris (brentuximab vedotin) / Takeda, Pfizer
Trial completion: Brentuximab Vedotin Prevention of (GVHD) After Unrelated Allogeneic Stem Cell Transplantation (clinicaltrials.gov) - Apr 20, 2019
P1, N=17, Completed, Sponsor: Washington University School of Medicine
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | NN1213 / Novo Nordisk
Trial completion date: Pilot Study of Redirected Haploidentical Natural Killer Cell Infusions for B-Lineage Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Apr 20, 2019
P1, N=20, Suspended, Sponsor: National University Health System, Singapore
Active, not recruiting --> Completed Trial completion date: Feb 2018 --> Feb 2020
- | Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi, Rituxan (rituximab) / Roche
Enrollment change, Trial termination: Rituximab in Preventing Acute Graft-Versus-Host Disease in a Donor Stem Cell Transplant for Hematologic Cancer (clinicaltrials.gov) - Feb 26, 2019
P2, N=20, Terminated, Sponsor: University of Nebraska
Trial completion date: Feb 2018 --> Feb 2020 N=50 --> 20 | Active, not recruiting --> Terminated; Study was closed to accrual for safety related to the frequency of BK infections.
- | Enrollment closed, Phase classification: A Study for Older Adults With Acute Lymphoblastic Leukaemia (clinicaltrials.gov) - Feb 15, 2019
P2, N=126, Active, not recruiting, Sponsor: University College, London
N=50 --> 20 | Active, not recruiting --> Terminated; Study was closed to accrual for safety related to the frequency of BK infections. Recruiting --> Active, not recruiting | Phase classification: P3 --> P2
- | alisertib (MLN8237) / Puma, Istodax (romidepsin) / Astellas, BMS
Trial completion, Enrollment change: Alisertib and Romidepsin in Treating Patients With Relapsed or Refractory B-Cell or T-Cell Lymphomas (clinicaltrials.gov) - Jan 28, 2019
P1, N=26, Completed, Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting | Phase classification: P3 --> P2 Active, not recruiting-> Completed | N=42 --> 26
- | NN1213 / Novo Nordisk
Trial completion, Phase classification: Red Cell Transfusion Goals in Patients With Acute Leukemias (clinicaltrials.gov) - Jan 24, 2019
P1, N=90, Completed, Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Active, not recruiting-> Completed | N=42 --> 26 Active, not recruiting --> Completed | Phase classification: PN/A --> P1
- | mycophenolate mofetil / Generic mfg., sirolimus / Generic mfg.
Trial completion: Inducible Regulatory T Cells (iTregs) in Non-Myeloablative Sibling Donor Peripheral Blood Stem Cell Transplantation (clinicaltrials.gov) - Jan 18, 2019
P1, N=16, Completed, Sponsor: Masonic Cancer Center, University of Minnesota
Active, not recruiting --> Completed | Phase classification: PN/A --> P1 Active, not recruiting --> Completed
- | Zeltherva (galinpepimut-S) / SELLAS Life Sciences
Trial completion, Trial completion date, Trial primary completion date: WT1 Vaccine Treatment of Patients in Remission From Acute Myeloid Leukemia (AML) or Acute Lymphoblastic Leukemia (ALL) (clinicaltrials.gov) - Nov 30, 2018
P2, N=22, Completed, Sponsor: Sellas Life Sciences Group
Active, not recruiting --> Completed Active, not recruiting --> Completed | Trial completion date: Dec 2018 --> Feb 2018 | Trial primary completion date: Dec 2018 --> Feb 2018
- | Campath (alemtuzumab) / Sanofi
Trial termination: Campath-1H and Allogeneic Blood Stem Cell Transplantation for Lymphoid Malignancies (clinicaltrials.gov) - Nov 7, 2018
P=N/A, N=19, Terminated, Sponsor: M.D. Anderson Cancer Center
Active, not recruiting --> Completed | Trial completion date: Dec 2018 --> Feb 2018 | Trial primary completion date: Dec 2018 --> Feb 2018 Completed --> Terminated
- | Trial completion, Trial completion date, Trial primary completion date: Fludarabine/Busulfan and Cyclophosphamide Conditioning for Adult Lymphoid Malignancies (clinicaltrials.gov) - Oct 17, 2018
P2, N=31, Completed, Sponsor: Shanghai Jiao Tong University School of Medicine
Completed --> Terminated Recruiting --> Completed | Trial completion date: Jun 2017 --> Oct 2018 | Trial primary completion date: Dec 2016 --> Jun 2018
- | decitabine / Generic mfg.
Trial completion: Phase I, Dose Escalation Study of Decitabine (clinicaltrials.gov) - Oct 15, 2018
P1, N=3, Completed, Sponsor: University of Florida
Recruiting --> Completed | Trial completion date: Jun 2017 --> Oct 2018 | Trial primary completion date: Dec 2016 --> Jun 2018 Active, not recruiting --> Completed
- | bortezomib / Generic mfg.
Trial completion, Trial completion date, Trial primary completion date, Combination therapy: Bortezomib and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Oct 10, 2018
P2, N=18, Completed, Sponsor: Stanford University
Active, not recruiting --> Completed Active, not recruiting --> Completed | Trial completion date: Sep 2018 --> Jul 2017 | Trial primary completion date: Sep 2017 --> Nov 2016
- | Trial termination: Study of Previously Collected and Stored Tissue Samples From Patients Previously Enrolled in a Completed National Cancer Institute Clinical Trial (clinicaltrials.gov) - Oct 5, 2018
P=N/A, N=241, Terminated, Sponsor: National Institutes of Health Clinical Center (CC)
Active, not recruiting --> Completed | Trial completion date: Sep 2018 --> Jul 2017 | Trial primary completion date: Sep 2017 --> Nov 2016 Completed --> Terminated
- | alisertib (MLN8237) / Puma, Istodax (romidepsin) / Astellas, BMS
Enrollment closed, Enrollment change, Trial primary completion date: Alisertib and Romidepsin in Treating Patients With Relapsed or Refractory B-Cell or T-Cell Lymphomas (clinicaltrials.gov) - Sep 19, 2018
P1, N=42, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Completed --> Terminated Completed --> Active, not recruiting | N=26 --> 42 | Trial primary completion date: Apr 2018 --> Oct 2018
- | cyclophosphamide / Generic mfg., busulfan / Generic mfg.
Trial completion, Enrollment change, Post-transplantation: Combination Chemotherapy, Bone Marrow Transplant, and Post Transplant Cyclophosphamide for Hematologic Cancer (clinicaltrials.gov) - Aug 31, 2018
P2, N=142, Completed, Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Completed --> Active, not recruiting | N=26 --> 42 | Trial primary completion date: Apr 2018 --> Oct 2018 Active, not recruiting --> Completed | N=92 --> 142
- | Neupogen (filgrastim) / Kyowa Kirin, Amgen
Phase classification, Enrollment change, Trial termination: Ex Vivo Expansion of Mafosfamide Purged CD34+ Cells in Patients With Acute Leukemia (clinicaltrials.gov) - Aug 23, 2018
P1, N=7, Terminated, Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Active, not recruiting --> Completed | N=92 --> 142 Phase classification: P=N/A --> P1 | N=25 --> 7 | Active, not recruiting --> Terminated; Expiration of study supply
- | Trial completion date, Trial termination: Genetic Susceptibility and Risk of Second Cancers in Patients Who Have Undergone Stem Cell Transplant for Cancer (clinicaltrials.gov) - Aug 16, 2018
P=N/A, N=1000, Terminated, Sponsor: Vanderbilt-Ingram Cancer Center
Phase classification: P=N/A --> P1 | N=25 --> 7 | Active, not recruiting --> Terminated; Expiration of study supply Trial completion date: Dec 2020 --> Feb 2018 | Active, not recruiting --> Terminated; Low accrual
- | Trial completion: Effect of Bovine Colostrum on Toxicity and Inflammatory Responses (clinicaltrials.gov) - Aug 1, 2018
P=N/A, N=62, Completed, Sponsor: Steffen Husby
Trial completion date: Dec 2020 --> Feb 2018 | Active, not recruiting --> Terminated; Low accrual Recruiting --> Completed
- | Trial completion, Trial completion date, Trial primary completion date: Collecting and Storing Malignant, Borderline Malignant Neoplasms, and Related Samples From Young Patients With Cancer (clinicaltrials.gov) - Jul 19, 2018
P=N/A, N=2545, Completed, Sponsor: Children's Oncology Group
Recruiting --> Completed Active, not recruiting --> Completed | Trial completion date: Jan 2100 --> Jun 2018 | Trial primary completion date: Jan 2100 --> Jun 2018
- Graspa (eryaspase) / PHAXIAM Therap
Enrollment change, Trial completion date, Trial termination, Combination therapy: L-asparaginase Encapsulated in Red Blood Cells (Eryaspase) for Treatment of Adult Patients With ALL or LBL (clinicaltrials.gov) - Jul 5, 2018
P1, N=14, Terminated, Sponsor: ERYtech Pharma
Active, not recruiting --> Completed | Trial completion date: Jan 2100 --> Jun 2018 | Trial primary completion date: Jan 2100 --> Jun 2018 N=24 --> 14 | Trial completion date: Dec 2017 --> Mar 2018 | Recruiting --> Terminated; Sponsor decision based off site/PI feedback about
- | Trial completion, Biopsy: Magnetic Acupressure in Reducing Pain in Cancer Patients Undergoing Bone Marrow Aspiration and Biopsy (clinicaltrials.gov) - Jun 28, 2018
P=N/A, N=83, Completed, Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
N=24 --> 14 | Trial completion date: Dec 2017 --> Mar 2018 | Recruiting --> Terminated; Sponsor decision based off site/PI feedback about Recruiting --> Completed
- | Trial completion, HEOR: Massage Therapy Given by Caregiver in Treating Quality of Life of Young Patients Undergoing Treatment for Cancer (clinicaltrials.gov) - Jun 2, 2018
P=N/A, N=80, Completed, Sponsor: Wake Forest University Health Sciences
Recruiting --> Completed Active, not recruiting --> Completed
- | NN1213 / Novo Nordisk
Trial completion, Trial completion date: Ultra-Low Dose IL-2 Therapy as GVHD Prophylaxis in Haploidentical Allogeneic Stem Cell Transplantation (clinicaltrials.gov) - Jun 1, 2018
P1, N=24, Completed, Sponsor: National Heart, Lung, and Blood Institute (NHLBI)
Active, not recruiting --> Completed Active, not recruiting --> Completed | Trial completion date: Jun 2019 --> May 2018
- | alisertib (MLN8237) / Puma, Istodax (romidepsin) / Astellas, BMS
Trial completion, Enrollment change: Alisertib and Romidepsin in Treating Patients With Relapsed or Refractory B-Cell or T-Cell Lymphomas (clinicaltrials.gov) - May 3, 2018
P1, N=26, Completed, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed | Trial completion date: Jun 2019 --> May 2018 Active,not recruiting --> Completed | N=42 --> 26
- | Phase classification, Trial completion date, Trial primary completion date: Red Cell Transfusion Goals in Patients With Acute Leukemias (clinicaltrials.gov) - Apr 19, 2018
P=N/A, N=90, Active, not recruiting, Sponsor: Sidney Kimmel Comprehensive Cancer Center
Active,not recruiting --> Completed | N=42 --> 26 Phase classification: P1 --> P=N/A | Trial completion date: Jun 2017 --> Dec 2019 | Trial primary completion date: Apr 2017 --> Dec 2018
- | zoledronic acid / Generic mfg.
Phase classification: Zometa Study in Pediatric Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Apr 18, 2018
P3, N=95, Completed, Sponsor: Children's Cancer Hospital Egypt 57357
Phase classification: P1 --> P=N/A | Trial completion date: Jun 2017 --> Dec 2019 | Trial primary completion date: Apr 2017 --> Dec 2018 Phase classification: P=N/A --> P3
- | Rituxan (rituximab) / Roche, Yervoy (ipilimumab) / BMS
Trial completion, Combination therapy: Ipilimumab and Rituximab in Treating Patients With Relapsed or Refractory B-cell Lymphoma (clinicaltrials.gov) - Apr 11, 2018
P1, N=32, Completed, Sponsor: National Cancer Institute (NCI)
Phase classification: P=N/A --> P3 Active, not recruiting --> Completed
- | Zolinza (vorinostat) / Merck (MSD), alisertib (MLN8237) / Puma
Trial completion, Enrollment change, Combination therapy, Epigenetic controller: Alisertib in Combination With Vorinostat in Treating Patients With Relapsed or Recurrent Hodgkin Lymphoma, B-Cell Non-Hodgkin Lymphoma, or Peripheral T-Cell Lymphoma (clinicaltrials.gov) - Apr 11, 2018
P1, N=34, Completed, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Active, not recruiting --> Completed | N=60 --> 34
- | Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi
Trial completion date: Phase 2 Haplotype Mismatched HSCT in Patients With Hematological Malignancies (clinicaltrials.gov) - Apr 10, 2018
P2, N=9, Terminated, Sponsor: Sherif S. Farag
Active, not recruiting --> Completed | N=60 --> 34 Trial completion date: May 2016 --> Jul 2017
- | Trial completion, Trial completion date, Trial primary completion date: Novel Approaches for Graft-versus-Host Disease Prevention Compared to Contemporary Controls (BMT CTN 1203) (clinicaltrials.gov) - Apr 6, 2018
P2, N=279, Completed, Sponsor: National Heart, Lung, and Blood Institute (NHLBI)
Trial completion date: May 2016 --> Jul 2017 Active, not recruiting --> Completed | Trial completion date: Dec 2018 --> Oct 2017 | Trial primary completion date: Aug 2018 --> Oct 2017
- | Januvia (sitagliptin) / Merck (MSD)
Trial completion, Trial completion date: Multicenter Phase II of CD26 Using Sitagliptin for Engraftment After UBC Transplant (clinicaltrials.gov) - Mar 14, 2018
P2, N=19, Completed, Sponsor: Sherif S. Farag
Active, not recruiting --> Completed | Trial completion date: Dec 2018 --> Oct 2017 | Trial primary completion date: Aug 2018 --> Oct 2017 Active, not recruiting --> Completed | Trial completion date: Nov 2018 --> Dec 2017
- Vyxeos (cytarabine/daunorubicin liposomal formulation) / Jazz, Nippon Shinyaku
Trial withdrawal: Pharmacokinetic and Pharmacodynamic Assessment of Treatment With CPX-351 (Cytarabine: Daunorubicin) Liposome for Injection in Acute Leukemias and MDS Patients With Moderate Hepatic Impairment (clinicaltrials.gov) - Mar 14, 2018
P2, N=0, Withdrawn, Sponsor: Jazz Pharmaceuticals
Active, not recruiting --> Completed | Trial completion date: Nov 2018 --> Dec 2017 Recruiting --> Withdrawn
- | Epratucyn (epratuzumab) / Gilead
Trial completion, IO biomarker: CHEPRALL: Multi-centric Study (clinicaltrials.gov) - Feb 27, 2018
P2, N=57, Completed, Sponsor: Nantes University Hospital
Recruiting --> Withdrawn Recruiting --> Completed
- cyclophosphamide / Generic mfg., clofarabine / Generic mfg.
Trial termination: POE07-01: Phase I Dose-Escalation Trial of Clofarabine Followed by Escalating Doses of Fractionated Cyclophosphamide in Children With Relapsed or Refractory Acute Leukemias (clinicaltrials.gov) - Feb 15, 2018
P1, N=35, Terminated, Sponsor: Sidney Kimmel Comprehensive Cancer Center
Recruiting --> Completed Active, not recruiting --> Terminated; Lack of accrual
- | Trial completion: Natural History Study of Fungal Infections of the Blood in Patients With Cancer or in Patients Who Have Undergone a Stem Cell Transplant (clinicaltrials.gov) - Feb 1, 2018
P=N/A, N=304, Completed, Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
Active, not recruiting --> Terminated; Lack of accrual Active, not recruiting --> Completed
- | Enrollment closed, Enrollment change: Ultra-Low Dose IL-2 Therapy as GVHD Prophylaxis in Haploidentical Allogeneic Stem Cell Transplantation (clinicaltrials.gov) - Jan 30, 2018
P1, N=20, Active, not recruiting, Sponsor: National Heart, Lung, and Blood Institute (NHLBI)
Active, not recruiting --> Completed Recruiting --> Active, not recruiting | N=40 --> 20
- | Trial completion: Caregiver Support in the Coping of Patients Who Are Undergoing a Donor Bone Marrow Transplant (clinicaltrials.gov) - Jan 26, 2018
P=N/A, N=36, Completed, Sponsor: The Cleveland Clinic
Recruiting --> Active, not recruiting | N=40 --> 20 Active, not recruiting --> Completed
- | atorvastatin / Generic mfg.
Trial completion, Trial primary completion date: Safety & Efficacy of Atorvastatin for Prophylaxis of Acute Graft Versus Host Disease in Patients With Hematological Malignancies HLA- Donor Hematopoietic Stem Cell Transplantation (clinicaltrials.gov) - Jan 23, 2018
P2, N=40, Completed, Sponsor: Ohio State University Comprehensive Cancer Center
Active, not recruiting --> Completed Active, not recruiting --> Completed | Trial primary completion date: Dec 2016 --> Jan 2014
- | bortezomib / Generic mfg.
Enrollment closed, Combination therapy: Bortezomib and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Jan 23, 2018
P2, N=18, Active, not recruiting, Sponsor: Stanford University
Active, not recruiting --> Completed | Trial primary completion date: Dec 2016 --> Jan 2014 Terminated --> Active, not recruiting
- | cyclophosphamide / Generic mfg.
Trial completion, Post-transplantation: Post-transplantation Cyclophosphamide as GVHD Prophylaxis After HSCT (clinicaltrials.gov) - Jan 16, 2018
P2, N=200, Completed, Sponsor: Ivan S Moiseev
Terminated --> Active, not recruiting Active, not recruiting --> Completed
- | Trial primary completion date: AMC-HEMREG-ALL: Acute Lymphoblastic Leukemia Registry at Asan Medical Center (clinicaltrials.gov) - Jan 10, 2018
P=N/A, N=200, Terminated, Sponsor: Asan Medical Center
Active, not recruiting --> Completed Trial primary completion date: Dec 2047 --> May 2016
- | Rituxan (rituximab) / Roche
Trial completion, Enrollment change, Post-transplantation: Rituximab in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant for Relapsed or Refractory B-cell Lymphoma (clinicaltrials.gov) - Jan 2, 2018
P2, N=63, Completed, Sponsor: Fred Hutchinson Cancer Research Center
Trial primary completion date: Dec 2047 --> May 2016 Active, not recruiting --> Completed | N=100 --> 63
- | New P1 trial: A Pilot Study to Determine the Safety and Tolerability of Sirolimus Given With Hyper-CVAD Chemotherapy (clinicaltrials.gov) - Dec 19, 2017
P1, N=7, Completed, Sponsor: Sidney Kimmel Cancer Center at Thomas Jefferson University
- | Phase classification: A Pilot Study to Determine the Safety and Tolerability of Sirolimus Given With Hyper-CVAD Chemotherapy (clinicaltrials.gov) - Dec 19, 2017
P1, N=7, Completed, Sponsor: Sidney Kimmel Cancer Center at Thomas Jefferson University
Active, not recruiting --> Completed | N=100 --> 63 Phase classification: P=N/A --> P1
- | Enrollment closed: Collecting and Storing Malignant, Borderline Malignant Neoplasms, and Related Samples From Young Patients With Cancer (clinicaltrials.gov) - Dec 13, 2017
P=N/A, N=3000, Active, not recruiting, Sponsor: Children's Oncology Group
Phase classification: P=N/A --> P1 Recruiting --> Active, not recruiting
- | Epratucyn (epratuzumab) / Gilead
Trial completion: Chemoimmunotherapy With Epratuzumab in Relapsed Acute Lymphoblastic Leukemia (ALL) (clinicaltrials.gov) - Dec 12, 2017
P2, N=134, Completed, Sponsor: Children's Oncology Group
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- | Trial primary completion date: Stem Cell Transplantation for Hematological Malignancies (clinicaltrials.gov) - Dec 5, 2017
P2/3, N=11, Terminated, Sponsor: Masonic Cancer Center, University of Minnesota
Active, not recruiting --> Completed Trial primary completion date: Oct 2012 --> Feb 2012